Reduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke

Aims To investigate the effect of oral isoflavone supplement on vascular endothelial function in patients with established cardiovascular disease. Methods and results A randomized, double-blinded, placebo-controlled trial was performed to determine the effects of isoflavone supplement (80 mg/day, n...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal 2008-11, Vol.29 (22), p.2800-2807
Main Authors: Chan, Yap-Hang, Lau, Kui-Kai, Yiu, Kai-Hang, Li, Sheung-Wai, Chan, Hiu-Ting, Fong, Daniel Yee-Tak, Tam, Sidney, Lau, Chu-Pak, Tse, Hung-Fat
Format: Article
Language:English
Subjects:
Aged
Atherosclerosis - drug therapy
Atherosclerosis - physiopathology
Brachial Artery - drug effects
Brachial Artery - physiology
C-reactive protein
C-Reactive Protein - metabolism
Double-Blind Method
Endothelial dysfunction
Endothelium, Vascular - drug effects
Female
Humans
Isoflavone
Isoflavones - administration & dosage
Isoflavones - therapeutic use
Male
Oxidative Stress - drug effects
Oxidative Stress - physiology
Placebos
Soybean Proteins - therapeutic use
Stroke - drug therapy
Stroke - physiopathology
Vasodilation - drug effects
Vasodilation - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims To investigate the effect of oral isoflavone supplement on vascular endothelial function in patients with established cardiovascular disease. Methods and results A randomized, double-blinded, placebo-controlled trial was performed to determine the effects of isoflavone supplement (80 mg/day, n = 50) vs. placebo (n = 52) for 12 weeks on brachial flow-mediated dilatation (FMD) in patients with prior ischaemic stroke. Compared with controls, FMD at 12 weeks was significantly greater in isoflavone-treated patients [treatment effect 1.0%, 95% confidence interval (95% CI) 0.1–2.0, P = 0.035]. Adjusted for baseline differences in FMD, isoflavone treatment was independently associated with significantly less impairment of FMD at 12 weeks (odds ratio 0.32, 95% CI 0.13–0.80, P = 0.014). The absolute treatment effect of isoflavone on brachial FMD was inversely related to baseline FMD (r = −0.51, P < 0.001), suggesting that vasoprotective effect of isoflavone was more pronounced in patients with more severe endothelial dysfunction. Moreover, isoflavone treatment for 12 weeks resulted in a significant decrease in serum high-sensitivity (hs)-C-reactive protein level (treatment effect −1.7 mg/L, 95% CI −3.3 to −0.1, P = 0.033). Nevertheless, isoflavone did not have any significant treatment effects on nitroglycerin-mediated dilatation, blood pressure, heart rate, serum levels of fasting glucose and insulin, haemoglobin A1c, and oxidative stress as determined by serum superoxide dismutase, 8-isoprostane, and malondialdehyde (all P > 0.05). Conclusion This study demonstrated that 12 week isoflavone treatment reduced serum hs-C-reactive protein and improved brachial FMD in patients with clinically manifest atherosclerosis, thus reversing their endothelial dysfunction status. These findings may have important implication for the use of isoflavone for secondary prevention in patients with cardiovascular disease, on top of conventional interventions.
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/ehn409